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Summary 
Eighty-six patients with advanced colorectal, gastric or pancreatic carcinoma and no prior exposure to 
chemotherapy were treated with brequinar sodium. Brequinar was administered at a median weekly dose of 
1200 mg/m 2 intravenously. The toxicity was moderate, with thirty patients (35%) experiencing grade 3 or 
4 toxicity. Objective responses were observed in 1/32 evaluable colorectal and 2/29 evaluable gastric carcino- 
ma patients. There were no objective responses in 17 evaluable pancreatic cancer patients. We conclude that, 
at this dose and schedule, brequinar does not have sufficient activity in these gastrointestinal malignancies 
to warrant further evaluation. 
Introduction 
Brequinar is a novel antimetabolite which interferes 
with dihydrooratate dehydrogenase, an enzyme 
crucial for pyrimidine biosynthesis [1]. Brequinar 
was selected for clinical development because of its 
broad antitumor activity in routine models (LI210 
leukemia and B16 melanoma) and human tumor 
xenografts (breast MX-1), colon (CX-1), lung 
(LX-1), and gastric (BL/STX-1) [2]. 
A number of phase I studies utilizing different 
dose levels and schedules have been reported [3-8]. 
In these phase I studies, the dose-limiting toxicities 
included thrombocytopenia and mucositis/stoma- 
titis. Minor responses were seen in advanced blad- 
der, lung, lymphoma and thyroid carcinoma [3, 5, 
8]. The weekly schedule was selected for phase II 
evaluation because of the superior dose intensity 
achieved in comparison with that previously ob- 
tained in the phase I schedules. In addition, the 
pharmacokinetic profile indicated a half-life of 15 
hours, resulting in prolonged drug exposure when 
this schedule was used [3]. Preclinical studies also 
suggested that efficacy was achieved by prolonged 
exposure [9, 10]. 
On the basis of the phase I experience, the recom- 
mended phase II starting dose and schedule was 
1800 mg/m 2 weekly [5, 6]. Early in the phase II 
evaluation of brequinar in several tumor categories, 
this starting dose resulted in unacceptable toxicity 
[11]. Therefore, the starting dose was reduced to 
1200 mg/m 2 weekly. This multicenter study was 
designed to evaluate the activity of brequinar in pa- 
tients with advanced colorectal, gastric or pancreat- 
ic carcinoma who had received no prior chemo- 
therapy. 
Patients and methods 
Criteria for inclusion in the study were perfor- 
mance status of < 2 (WHO scale), life expectancy 
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Table 1. Patient and treatment characteristics 
Characteristics Colorectal Gastric Pancreas 
Total patients 35 32 19 
(inevaluable/not eligible) (3/2) (3/1) (2/0) 
Male:Female 25/10 28/4 14/5 
Median age (range) 62 (40-75) 66 (37-79) 62 (25-72) 
Performance status* 
0 14 10 8 
1 16 19 8 
2 5 3 3 
Prior therapy 
Surgery 35 26 11 
Radiation therapy 4 4 0 
Biological therapy 3 0 0 
Chemotherapy 0 0 0 
Sites of metastases (%) 
Liver 25 (71) 21 (66) 13 (68) 
Lung 12 (34) 5 (16) 1 (5) 
Lymph nodes 6 (17) 8 (25) 3 (16) 
Skin/subcutaneous tissue 0 (0) 4 (12) 0 (0) 
Other 9 (26) 9 (28) 4 (21) 
*World Health Organization criteria [12]. 
> 8 weeks, serum bilirubin < 1.5 mg/dl ,  serum 
creatinine < 2.0 mg/dl ,  absolute granulocyte count 
> 1,500 cells/ram 3, platelet count > 
100,000/mm 3, and presence of bidimensionally 
measurable disease. Informed consent was given by 
all patients in accordance with regulatory agency 
requirements. 
Brequinar was administered intravenously once 
weekly at a starting dose of 1800 m g / m  2 (8 pa- 
tients) or 1200 m g / m  2 (78 patients) in 500 ml of  
normal  saline over 1 - 2  hours. The subsequent dose 
of  brequinar was escalated or decreased according 
to predetermined criteria and depending on the tox- 
icities experienced in the preceding course. When 
necessary, dosing was delayed until the patient 
recovered f rom toxicities. Toxicity was coded by 
NCI common toxicity criteria (2/18/88 version). 
Patients were interviewed and examined prior to 
each dose of chemotherapy.  Labora tory  studies in- 
cluding complete blood cell, differential, and plate- 
let counts were repeated once a week. Total  protein, 
albumin, calcium, inorganic phosphorous,  glucose, 
blood urea nitrogen, creatinine, uric acid, total 
bilirubin, alkaline phosphatase,  lactic dehydro- 
genase, and electrolytes were assessed every four 
weeks. 
Response was evaluated every four weeks by ap- 
propriate radiologic studies and clinical measure- 
ment of  bidimensional lesions. Criteria for defining 
response were standard; except, palpable reduction 
in liver size was not utilized to designate a partial 
response. Patients were considered evaluable for 
response if they received at least one dose of brequi- 
nar and underwent a subsequent assessment of  their 
measurable disease. Patients who died of  disease 
without such an assessment were considered evalua- 
ble and classified as progressive disease. 
R e s u l t s  
From November  1988 to December 1990, 86 pa- 
tients with histologically documented, advanced, 
measurable colorectal, gastric or pancreatic carci- 
noma were entered in the study. Patient and treat- 
ment characteristics are listed in Table 1. The pa- 
tients had excellent performance status and limited 
exposure to prior therapy. The predominant  sites of  
measurable disease were liver, lung and lymph 
nodes. 
Dosing and treatment results are presented in 
Table 2. The 86 patients received 441 doses of  bre- 
Table 2. Dosing and treatment results 
Colorectal Gastric Pancreas 
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Doses administered 
Total 219 140 82 
Median 6 4 4 
Range 1-15 1-11 1 -8  
Median weekly dose-mg/m 2 1200 1200 1200 
Range (588-3110) 614-2300) (960-1800) 
Number of patients 
Dose escalation 13 8 7 
Dose reduction 11 11 3 
Receiving one dose only 4 5 4 
Treatment results 
Partial response 1 2 0 
Stable disease 8 7 4 
Progressive disease 23 20 13 
Table 3. Toxicity (all patients) 
Toxicity No. of patients by maximum grade 
Grade 1 Grade 2 Grade 3 Grade 4 
Anorexia 6 2 1 0 
Fatigue 10 2 0 0 
Nausea/vomiting 26 15 7 3 
Mucositis/stomatitis 12 7 5 3 
Rash 13 8 5 l 
Diarrhea 18 10 2 1 
Thrombocytopenia 8 15 5 7 
Anemia 5 18 11 1 
Leukopenia 9 7 2 0 
Granulocytopenia 5 9 2 1 
quinar (median 4, range 1-15).  In 28 patients dose 
escalation was possible and in 25 patients dose 
reduction was required. Thirteen patients received 
only one dose. The median weekly dose was 1200 
mg/m 2. Seventy-eight of  the 86 patients were 
evaluable for response. Three patients were deemed 
ineligible due to the absence of  a measurable lesion, 
and five additional patients were inevaluable due to 
early non-disease-related death and inability to ob- 
tain follow-up tumor measurements. Partial 
responses were observed in 2 gastric and 1 colorec- 
tal cancer patients. These responses were of 66, 100, 
and greater than 200 days duration respectively. 
There were no objective responses to patients with 
pancreatic cancer. 
All 86 patients are evaluable for toxicity. In 
general, the toxicity encountered in this phase II 
trial was moderate. The major non-hematologic 
and hematologic toxicities encountered are listed in 
Table 3. There were two treatment related deaths in 
patients with metastatic gastric cancer. One patient 
with extensive peritoneal carcinomatosis ex- 
perienced grade 4 thrombocytopenia and gastroin- 
testinal bleeding after his first dose of  brequinar 
(1800 mg/m2). The second patient, with extensive 
hepatic metastasis and a history of  diabetes, ex- 
perienced grade 4 thrombocytopenia and progres- 
sive deterioration of  renal function after receiving 
his eighth dose of brequinar (total dose 20 grams; 
starting dose 1200 mg/m2). The deterioration in 
renal function in this case was in part attributable 
to contrast employed in the follow-up radiographic 
evaluation of  measurable hepatic metastases. 
Seventeen episodes of grade 4 toxicity occurred 
64 
in 12 (1407o) patients (4 colorectal, 7 gastric, 1 pan- 
creatic). In 3 patients (2 colorectal, 1 gastric) these 
grade 4 toxicities were associated with the 1800 
mg/m 2 starting dose. The remaining instances of 
grade 4 toxicity occurred in patients whose starting 
dose was 1200 mg/m 2 and generally occurred dur- 
ing the early treatment doses. The grade 3 toxicities 
summarized in Table 3 occurred in 18 (2107o) pa- 
tients (9 colorectal, 6 gastric, 3 pancreatic). In 3 pa- 
tients (2 colorectal, 1 gastric) the starting dose was 
1800 mg/m 2. The remaining instances of grade 3 
toxicity occurred in patients whose starting dose 
was 1200 mg/m 2. 
Grade 3-4  toxicity was observed in 6 of the first 
8 patients (75%) entered at the initial starting dose 
of 1800 g/m 2. However, subsequent reduction in 
the starting dose to 1200 mg/m 2 resulted in a more 
acceptable level of grade 3-4  toxicity (24/78 pa- 
tients, 30070). Dose escalation was possible in 3207o 
(28/86) of patients; however, despite the reduction 
in starting dose, a further dose reduction was re- 
quired at some point in the course of treatment in 
29070 (25/86) of patients. The reduction in starting 
dose followed by additional escalations and reduc- 
tions based on individual patient tolerance account 
for the wide range (588-3110 mg/m 2) of doses ad- 
ministered to these patients with gastrointestinal 
malignancies. The observed variation in tolerance 
may, in part, reflect the magnitude of the hepatic 
involvement of individual patients in this study. 
Discussion 
The absence of objective responses in 17 evaluable 
patients with pancreatic cancer excludes a response 
rate of 20~ (one-sided 95070 confidence limit, 
16070). In addition, response rates of 3070 (1/32) in 
colorectal cancer (one-sided 9507o confidence limit, 
1507o) and 7070 (2/29) in gastric cancer (one-sided 
95070 confidence limit, 29070) are disappointing. On 
the basis of these results, we conclude that at this 
dose and on this schedule, brequinar sodium does 
not have sufficient activity to warrant further 
evaluation in patients with advanced gastrointesti- 
nal carcinoma. 
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